Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.

Valadão M, Braggio D, Santos AF, Pimenta-Inada HK, Linhares E, Gonçalves R, Romano S, Vilhena B, Small I, Cubero D, Cruz F, Oliveira AT, Martinho O, Reis RM, Guimarães DP, Ferreira CG.

J Surg Res. 2012 Nov;178(1):288-93. doi: 10.1016/j.jss.2012.03.031. Epub 2012 Apr 5.

PMID:
22516345
2.

The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.

Koh Y, Lee HE, Oh DY, Kim JH, Lee SH, Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ.

Jpn J Clin Oncol. 2012 Nov;42(11):1020-7. doi: 10.1093/jjco/hys138. Epub 2012 Sep 5.

PMID:
22952296
3.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
4.

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.

Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.

Ann Surg Oncol. 2007 Mar;14(3):1123-8. Epub 2006 Dec 31.

PMID:
17195905
5.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
6.

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.

Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.

Acta Oncol. 2012 Apr;51(4):528-36. doi: 10.3109/0284186X.2011.636753. Epub 2011 Dec 7.

PMID:
22150077
7.

Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.

Pantaleo MA, Nannini M, Saponara M, Gnocchi C, Di Scioscio V, Lolli C, Catena F, Astolfi A, Di Battista M, Biasco G; GIST Study Group, University of Bologna, Bologna, Italy..

Anticancer Drugs. 2012 Jun;23(5):567-72. doi: 10.1097/CAD.0b013e328352cc50.

PMID:
22430048
8.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
9.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738
10.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
11.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
12.

Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.

Thao le B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, Watanabe T, Sato Y.

Cancer Biol Ther. 2009 Apr;8(8):683-8.

PMID:
19417561
13.

Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.

Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF.

J Surg Oncol. 2010 Nov 1;102(6):599-603. doi: 10.1002/jso.21630.

PMID:
20976730
14.

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.

Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M.

Clin Cancer Res. 2012 Mar 15;18(6):1769-76. doi: 10.1158/1078-0432.CCR-11-2230. Epub 2012 Jan 26.

15.

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92. doi: 10.1073/pnas.0803383105. Epub 2008 Jun 11.

17.

[Translational research and diagnosis in GIST].

Wardelmann E.

Pathologe. 2012 Nov;33 Suppl 2:273-7. doi: 10.1007/s00292-012-1682-9. Review. German.

PMID:
22968735
18.

Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.

Sakamoto K, Sakurai S, Kanda T, Sakuma Y, Hishima T, Hironaka M, Bamba T, Keira Y, Takano Y, Niki T, Hasegawa T, Hirota S.

Cancer Sci. 2010 May;101(5):1270-8. doi: 10.1111/j.1349-7006.2010.01510.x. Epub 2010 Jan 22.

19.

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P.

Clin Cancer Res. 2008 Jul 15;14(14):4550-5. doi: 10.1158/1078-0432.CCR-08-0086.

20.

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.

J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.

PMID:
17458563

Supplemental Content

Support Center